Overview
Description
Nuformix Plc is a pharmaceutical company that focuses on the development of cocrystal technology for novel outcomes in drug efficacy and delivery. The company's primary function is to utilize its expertise in pharmaceutical cocrystal intellectual property to improve drug formulation, enhancing bioavailability and therapeutic outcomes. Nuformix targets a wide array of medical and health sectors, with particular emphasis on treating cancer and fibrotic diseases. By developing compositions that enhance existing drug compounds, the company contributes significantly to the pharmaceutical supply chain, creating solutions that can lead to more effective drug therapies. Its strategic role within the financial market highlights the importance of innovation in the biotech sector, aimed at addressing unmet clinical needs and improving patient care. As Nuformix continues to leverage its proprietary technology, it remains a pivotal player in advancing drug development processes and therapeutic innovations.
About
CEO
Employees
3
Address
60 Gracechurch Street
6th Floor
London, EC3V 0HR
6th Floor
London, EC3V 0HR
Phone
44 12 2362 7222
Website
Instrument type
Common stock
Sector
Healthcare
Industry
Biotechnology
Country
United Kingdom
MIC code
XLON